158 related articles for article (PubMed ID: 2409999)
1. Comparative effects of an antiviral drug, inosiplex, and diphosphonates in Paget's disease of bone.
Kanis JA; Preston CJ; Beard DJ; Beneton M; Harris S; Russell RG
Bone; 1985; 6(2):69-72. PubMed ID: 2409999
[TBL] [Abstract][Full Text] [Related]
2. Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget's disease of bone.
Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Vignon E; Trechsel U; Mathieu L; Edouard C
Adv Exp Med Biol; 1980; 128():299-309. PubMed ID: 6448538
[No Abstract] [Full Text] [Related]
3. Improvement in the deformity of the face in Paget's disease treated with diphosphonates.
Bickerstaff DR; Douglas DL; Burke PH; O'Doherty DP; Kanis JA
J Bone Joint Surg Br; 1990 Jan; 72(1):132-6. PubMed ID: 2137127
[TBL] [Abstract][Full Text] [Related]
4. Duration of effect of oral diphosphonate therapy in Paget's disease of bone.
Gray RE; Yates AJ; Preston CJ; Smith R; Russell RG; Kanis JA
Q J Med; 1987 Sep; 64(245):755-67. PubMed ID: 2966965
[TBL] [Abstract][Full Text] [Related]
5. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.
Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Edouard C; Vignon C; Mathieu L; Trechsel U
Lancet; 1979 Sep; 2(8141):489-92. PubMed ID: 90215
[TBL] [Abstract][Full Text] [Related]
6. Diphosphonates in Paget's disease.
Russell RG; Smith R; Preston C; Walton RJ; Woods CG
Lancet; 1974 May; 1(7863):894-8. PubMed ID: 4133419
[No Abstract] [Full Text] [Related]
7. Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget's disease of bone.
Douglas DL; Duckworth T; Kanis JA; Preston C; Beard DJ; Smith TW; Underwood I; Woodhead JS; Russell RG
Arthritis Rheum; 1980 Oct; 23(10):1185-92. PubMed ID: 6448604
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of Paget's disease of bone: diphosphonates or calcitonin?].
Davoine GA; Jung A; Courvoisier B
Schweiz Med Wochenschr; 1981 Apr; 111(15):518-24. PubMed ID: 6785879
[TBL] [Abstract][Full Text] [Related]
9. Intravenous clodronate in the treatment and retreatment of Paget's disease of bone.
Yates AJ; Percival RC; Gray RE; Atkins RM; Urwin GH; Hamdy NA; Preston CJ; Beneton MN; Russell RG; Kanis JA
Lancet; 1985 Jun; 1(8444):1474-7. PubMed ID: 2861411
[TBL] [Abstract][Full Text] [Related]
10. APD in Paget's disease of bone. Role of the mononuclear phagocyte system?
Bijvoet OL; Frijlink WB; Jie K; van der Linden H; Meijer CJ; Mulder H; van Paassen HC; Reitsma PH; te Velde J; de Vries E; van der Wey JP
Arthritis Rheum; 1980 Oct; 23(10):1193-204. PubMed ID: 6448605
[No Abstract] [Full Text] [Related]
11. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.
Harinck HI; Bijvoet OL; Blanksma HJ; Dahlinghaus-Nienhuys PJ
Clin Orthop Relat Res; 1987 Apr; (217):79-98. PubMed ID: 2951049
[TBL] [Abstract][Full Text] [Related]
12. Sustained biochemical effects of short treatment of Paget's disease of bone with dichloromethylene diphosphonate.
Chapuy MC; Charhon SA; Meunier PJ
Metab Bone Dis Relat Res; 1983; 4(6):325-8. PubMed ID: 6229683
[TBL] [Abstract][Full Text] [Related]
13. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
[TBL] [Abstract][Full Text] [Related]
14. Treatment of Paget's disease of bone with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate.
Adami S; Salvagno G; Guarrera G; Montesanti F; Garavelli S; Rosini S; Lo Cascio V
Calcif Tissue Int; 1986 Oct; 39(4):226-9. PubMed ID: 2947663
[TBL] [Abstract][Full Text] [Related]
15. Sequential treatment of Paget's disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP).
Adami S; Guarrera G; Salvagno G; Spiazzi G; Marini G; Rosini S; Lo Cascio V
Metab Bone Dis Relat Res; 1984; 5(6):265-7. PubMed ID: 6238218
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Paget's bone disease with the bisphosphonate APD.
Mautalen CA
Henry Ford Hosp Med J; 1983; 31(4):244-8. PubMed ID: 6425243
[No Abstract] [Full Text] [Related]
17. Prediction and assessment of the response of Paget's disease to bisphosphonate treatment.
Hosking DJ
Bone; 1999 May; 24(5 Suppl):69S-71S. PubMed ID: 10321933
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with the use of two diphosphonates in the treatment of Paget's disease.
Dewis P; Prasad BK; Anderson DC; Willets S
Ann Rheum Dis; 1985 Jan; 44(1):34-8. PubMed ID: 3918513
[TBL] [Abstract][Full Text] [Related]
19. Effective oral treatment of severe Paget's disease of bone with APD (3-amino-1-hydroxypropylidene-1,1-bisphosphonate); a comparison with combined calcitonin + EHDP (1-hydroxyethylidene-1,1-bisphosphonate).
Fraser TR; Ibbertson HK; Holdaway IM; Rutland M; King A; Dodd G; Wattie DJ
Aust N Z J Med; 1984 Dec; 14(6):811-8. PubMed ID: 6442563
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic strategy in Paget's disease of bone.
Meunier PJ; Vignot E
Bone; 1995 Nov; 17(5 Suppl):489S-491S. PubMed ID: 8573424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
